Literature DB >> 25486410

The ongoing debate of who to treat for chronic hepatitis C virus.

Marc G Ghany1.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 25486410      PMCID： PMC7470600          DOI： 10.1001/jamainternmed.2014.4299

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN： 2168-6106            Impact factor:   21.873


× No keyword cloud information.
  21 in total

Review 1.  Natural history of chronic hepatitis C.

Authors:  Leonard B Seeff
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

2.  Hepatitis C in the United States.

Authors:  Scott D Holmberg; Philip R Spradling; Anne C Moorman; Maxine M Denniston
Journal:  N Engl J Med       Date:  2013-05-16       Impact factor: 91.245

3.  Simeprevir (Olysio) for chronic hepatitis C.

Authors: 
Journal:  Med Lett Drugs Ther       Date:  2014-01-06       Impact factor: 1.909

4.  Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group.

Authors:  E Kenny-Walsh
Journal:  N Engl J Med       Date:  1999-04-22       Impact factor: 91.245

5.  Evaluation of liver disease progression in the German hepatitis C virus (1b)-contaminated anti-D cohort at 35 years after infection.

Authors:  Manfred Wiese; Janett Fischer; Micha Löbermann; Uwe Göbel; Kurt Grüngreiff; Wolfgang Güthoff; Ulrike Kullig; Franziska Richter; Ingolf Schiefke; Hannelore Tenckhoff; Alexander Zipprich; Thomas Berg; Tobias Müller
Journal:  Hepatology       Date:  2013-11-18       Impact factor: 17.425

6.  Increased all-cause, liver, and cardiac mortality among hepatitis C virus-seropositive blood donors.

Authors:  Anne M Guiltinan; Zhanna Kaidarova; Brian Custer; Jennie Orland; Angela Strollo; Sherri Cyrus; Michael P Busch; Edward L Murphy
Journal:  Am J Epidemiol       Date:  2008-01-17       Impact factor: 4.897

7.  Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis.

Authors:  Bart J Veldt; E Jenny Heathcote; Heiner Wedemeyer; Juerg Reichen; W Peter Hofmann; Stefan Zeuzem; Michael P Manns; Bettina E Hansen; Solko W Schalm; Harry L A Janssen
Journal:  Ann Intern Med       Date:  2007-11-20       Impact factor: 25.391

8.  Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

Authors:  Stefan Zeuzem; Ira M Jacobson; Tolga Baykal; Rui T Marinho; Fred Poordad; Marc Bourlière; Mark S Sulkowski; Heiner Wedemeyer; Edward Tam; Paul Desmond; Donald M Jensen; Adrian M Di Bisceglie; Peter Varunok; Tarek Hassanein; Junyuan Xiong; Tami Pilot-Matias; Barbara DaSilva-Tillmann; Lois Larsen; Thomas Podsadecki; Barry Bernstein
Journal:  N Engl J Med       Date:  2014-04-10       Impact factor: 91.245

9.  Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

Authors:  Adriaan J van der Meer; Bart J Veldt; Jordan J Feld; Heiner Wedemeyer; Jean-François Dufour; Frank Lammert; Andres Duarte-Rojo; E Jenny Heathcote; Michael P Manns; Lorenz Kuske; Stefan Zeuzem; W Peter Hofmann; Robert J de Knegt; Bettina E Hansen; Harry L A Janssen
Journal:  JAMA       Date:  2012-12-26       Impact factor: 56.272

10.  Diagnosis, management, and treatment of hepatitis C: an update.

Authors:  Marc G Ghany; Doris B Strader; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425
View more
  3 in total

1.  Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients.

Authors:  Alexis P Chidi; Cindy L Bryce; Julie M Donohue; Michael J Fine; Douglas P Landsittel; Larissa Myaskovsky; Shari S Rogal; Galen E Switzer; Allan Tsung; Kenneth J Smith
Journal:  Value Health       Date:  2016-03-24       Impact factor: 5.725

2.  Clinicians' Views of Hepatitis C Virus Treatment Candidacy With Direct-Acting Antiviral Regimens for People Who Inject Drugs.

Authors:  Alice K Asher; Carmen J Portillo; Bruce A Cooper; Carol Dawson-Rose; David Vlahov; Kimberly A Page
Journal:  Subst Use Misuse       Date:  2016-05-24       Impact factor: 2.164

3.  Developing and Using Therapeutics for Emerging Infections.

Authors:  Jeannine S McCune; Kellie S Reynolds
Journal:  Clin Pharmacol Ther       Date:  2015-10       Impact factor: 6.875
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.